ACRV (Acrivon Therapeutics) Institutional Ownership: 37.94% (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRV Acrivon Therapeutics Inc ACRV
35 GF Score
Price $1.72
! 3 Warning Signs
View Full Analysis

What is Acrivon Therapeutics Institutional Ownership?

Acrivon Therapeutics ACRV -0.29% 35 Institutional Ownership is 37.94% as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Acrivon Therapeutics's institutional ownership is 37.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Acrivon Therapeutics's Insider Ownership is 7.73%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Acrivon Therapeutics's Float Percentage Of Total Shares Outstanding is 66.96%.

Acrivon Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Acrivon Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrivon Therapeutics Institutional Ownership Chart

Acrivon Therapeutics Historical Data

The historical data trend for Acrivon Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 5.15 5.27 5.36 5.83 5.86 5.45 5.08 5.11 5.47 5.51
ACRV
35GF Score
Acrivon Therapeutics Inc ACRV
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acrivon Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 37.94% mean?
Acrivon Therapeutics (ACRV) has a Institutional Ownership of 37.94% as of Aug. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Acrivon Therapeutics and its competitors.
Is Acrivon Therapeutics' Institutional Ownership too high?
Acrivon Therapeutics' current Institutional Ownership is 37.94%. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Institutional Ownership compare to SPRO and BSEM?
Acrivon Therapeutics' Institutional Ownership of 37.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Acrivon Therapeutics and its competitors. Acrivon Therapeutics's current Institutional Ownership is 37.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Institutional Ownership of 37.94%. The current Institutional Ownership is 37.94%. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Institutional Ownership is 37.94% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrivon Therapeutics Business Description

Address 480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score

Get the complete analysis for ACRV

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price